Browsing category:

Anti-Migraine


Known as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults[…]

Read More

On January 15, 2015 Pernix Therapeutics excitedly announced an FDA acceptance for a priority review of Sumatriptan and Naproxen Sodium, also known as Treximet, for adolescent patients. Pernix expects an FDA approval by the second quarter of 2015, which would greatly benefit the adolescent patient population suffering from migraines. This anticipated approval would be specific[…]

Read More

On January 5, 2015 Jubilant Life Sciences received an FDA nod for their Rizatriptan generic formulation, paving the way for more generic forms of Merck’s blockbuster migraine medication Maxalt. The strengths approved for generic production are both 5 milligrams and 10 milligrams, which makes up an estimated 70 million dollar market. Rizatriptan is an efficacious[…]

Read More

Exciting news was disseminated from Avanir Pharmaceuticals’ on March 28, 2014 with their announcement that the FDA had accepted a New Drug Application for their intranasal form of Sumatriptan. Designed as a novel and investigational drug-device combination product coined AVP-825, this unique form of Sumatriptan is a breath powered, intranasal form of migraine treatment. The[…]

Read More

UPDATE: On May 6, 2014, Propranolol was approved by the European Commission for treatment of infantile hemangioma. Infantile hemangioma, or an overgrowth of blood vessels on or under the skin of infants is a benign vascular condition. As a common non-life threatening tumor of the skin, infantile hemangioma occur during the first four weeks of[…]

Read More

On March 11, 2014 the FDA approved Topiramate, marketed as Qudexy™ XR by Upsher-Smith Laboratories, for the treatment of partial-onset seizures (POS) or primary generalized tonic-clonic seizures in patients 10+ years of age. It is also approved as adjunctive therapy in patients 2+ years of age for the aforementioned seizures, and seizures associated with Lennox-Gastaut[…]

Read More

The latest news regarding divalproex sodium is exciting for patients who suffer from migraine headaches. A new set of guidelines were published in the April 24, 2012 issue of Neurology, and presented at the academy’s annual meeting in New Orleans April 21 to 28, 2013.  The new guidelines are composed of information from 29 studies[…]

Read More

Eletriptan Hydrobromide, CAS number 143322-58-1, is a medication indicated for the acute treatment of migraine with or without aura in adults. Known as Relpax, which is marketed by Pfizer, the patent expiration for Eletriptan Hydrobromide is on December 26, 2016 (Patent Use Code U – 876 – TREATMENT OF MIGRAINE WITH OR WITHOUT AURA). Available in[…]

Read More

Topiramate CAS# 97240-79-4, is also known as the brand name medication Topamax. Marketed by Janssen, Topamax has a patent expiration of October 13, 2015. As an effectual and reliable medication to treat patients with both epilepsy and migraines, topiramate is known for it’s effectiveness as monotherapy or adjunctive therapy for the treatment of epilepsy. Tablets[…]

Read More

On November 14th, 2012 Zomig went off-patent, opening the door for generic versions of this formidable product. As an efficacious treatment for patients suffering from migraines with or without auras, zolmitriptan is also known as Zomig, marketed by AstraZeneca. Offered in both oral and orally disintegrating tablets, in 2.5 or 5 milligram tablets, zolmitriptan has[…]

Read More